BACKGROUND: Recent characterization of @entity3009 receptor subtypes shows that each is critical to cellular functions and operates through separate signaling pathways that may explain differing effects of @entity2918 . This study aimed to determine whether @entity3009 receptors @entity7701 and @entity2912 are modulated after injury and to evaluate the effect of @entity1421 ( @entity1421 ) addition and blockade on EP receptor expression. METHODS: Peripheral blood mononuclear cells (PBMCs) isolated from 10 @entity1 sustaining @entity174 or @entity130 and 10 control subjects were stimulated with lipopolysaccharide +/- @entity8228 , an inhibitor of @entity1421 production. Samples were evaluated for production of @entity1421 , @entity5 @entity39 factor--alpha, and @entity8285 as well as mRNA expression of EP receptors and @entity2247 . EP receptor expression was also evaluated after treating control PBMCs with @entity1421 . RESULTS: PBMCs from injured @entity1 exhibited significant increases in @entity1421 production and @entity2247 mRNA compared with control subjects, and these increases were inhibited by @entity8228 . In contrast, @entity7701 and @entity2912 receptors were markedly down-regulated after injury and @entity8228 restored expression to control levels. Decreased @entity7701 and @entity2912 receptor expression after injury was replicated by coincubation of PBMCs with @entity1421 . CONCLUSIONS: Specific PGE(2) receptors are down-regulated after injury and @entity8228 reverses this response. Furthermore, @entity1421 mediates @entity7701 and @entity2912 down-regulation. These data suggest that specific EP receptor subtypes may provide critical targets for augmenting the immune response after injury in @entity1 .

@entity3009 E2 receptors XXXX and @entity2912 are down-regulated in @entity1 mononuclear cells after injury.

@entity1 :: ('9606', 'Species') :: ['humans', 'patients'] @entity8285 :: ('MESH:D007975', 'Chemical') :: ['leukotriene B(4)'] @entity174 :: ('MESH:D050723', 'Disease') :: ['fracture'] @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity1421 :: ('MESH:D015232', 'Chemical') :: ['PGE(2)', 'prostaglandin E(2)'] @entity2912 :: ('5734', 'Gene') :: ['EP4'] @entity2918 :: ('MESH:D011453', 'Chemical') :: ['prostanoids'] @entity3009 :: ('CHEBI:26333', 'Chemical') :: ['prostaglandin'] @entity7701 :: ('5732', 'Gene') :: ['EP2'] @entity2247 :: ('4513', 'Gene') :: ['COX-2'] @entity130 :: ('MESH:D014947', 'Disease') :: ['burn injury'] @entity8228 :: ('MESH:C080955', 'Chemical') :: ['NS-398']
@entity7701 :: (5732,Gene) :: ['EP2']
